Tipranavir

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tipranavir
Tipranavir structure 2.svg
Clinical data
Pronunciation tip-RA-nə-veer
Trade names Aptivus
AHFS/Drugs.com Monograph
MedlinePlus a606009
License data
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration
By mouth (soft capsules)
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 99.9%
Metabolism Hepatic
Biological half-life 4.8–6 hours
Excretion Feces (82.3%), urine (4.4%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
NIAID ChemDB
PDB ligand
ECHA InfoCard 100.158.066
Chemical and physical data
Formula C31H33F3N2O5S
Molar mass 602.66 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Tipranavir (TPV), or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer Ingelheim under the trade name Aptivus AP-ti-vus. It is administered with ritonavir in combination therapy to treat HIV infection.

Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.[1] Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008.[2]

Tipranavir should only be taken in combination with ritonavir and other antiretroviral drugs, and is not approved for treatment-naïve patients.[3] Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with drug resistance. However, side effects of tipranavir may be more severe than those of other antiretrovirals. Some side effects include intracranial hemorrhage, hepatitis, hepatic decompensation, hyperglycemia and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.[3]

Aptivus labeling has a black box warning regarding hepatotoxicity and intracranial hemorrhage.[3]

References[edit]

  1. ^ Doyon, L; Tremblay, S; Bourgon, L; Wardrop, E; Cordingley, MG (October 2005). "Selection and Characterization of HIV-1 Showing Reduced Susceptibility to the Non-Peptidic Protease Inhibitor Tipranavir". Antiviral Research. 68 (1): 27–35. doi:10.1016/j.antiviral.2005.07.003. PMID 16122817. 
  2. ^ "New Aptivus (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients" (Press release). Boehringer Ingelheim. 2008-06-24. Retrieved 2008-09-02. 
  3. ^ a b c "Aptivus (tipranavir) Capsules, Oral Solution. Full Prescribing Information" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc.